Z-2201-2021 Class III Terminated

Recalled by Stanbio Laboratory, LP — Boerne, TX

FDA device recall Z-2201-2021 was initiated by Stanbio Laboratory, LP on Jul 12, 2021 and is designated Class III. Reason for recall: Deterioration in the stability of the reagents which has resulted in lower than expected or out of range Quality Control values. The recall status is terminated (terminated Mar 29, 2022). Affected quantity: 100 units.

Recall details

Product Type
Devices
Report Date
Aug 11, 2021
Initiation Date
Jul 12, 2021
Termination Date
Mar 29, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
100 units

Product description

Synchron CX/DX/LX Beta-Hydroxybutyrate . in vitro diagnostic reagent.

Reason for recall

Deterioration in the stability of the reagents which has resulted in lower than expected or out of range Quality Control values.

Distribution pattern

Worldwide distribution - U.S. Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KY, LA, MA, MD, MI, MO, NC, NH, NJ, NV, NY, OH, OK, OR, PA, Puerto Rico, RI, TN, TX, VA, VT, WA, WI, and WV. The countries of Australia, Canada, Chile, Federal Republic of Germany, Hong Kong, Singapore, Taiwan, Thailand, United Kingdom, and Viet Nam.

Code information

Catalog Number/Product Description: B2440-180/Synchron CX/DX/LX ¿-Hydroxybutyrate LiquiColor Device Identifier: 00657498000526 Lot Numbers: 161020;

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-2201-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-2201-2021. Report a data issue: hello@regdatalab.com.